Hossein Borghaei, DO, MS of Fox Chase Cancer Center, Philadelphia, PA gives an outline of his talk on the different anti-PD-L1 and PD-1 antibodies in the market for non-small cell lung cancer (NSCLC) held at the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria. . The PD-L1 inhibitor, avelumab, has an additional property called antibody dependent cellular cytotoxicity (ADCC). Strategies to augment the ADCC component of avelumab may allow for treatment of patients who do not have robust responses to single agent anti-PD-L1s. The use of genetic manipulations inhibiting a particular pathway in conjunction with the antibody that induces ADCC, results in much more lysis of cancer cells. Dr Borghaei says this is still in the experimental stage, and more work is required.
Avelumab and antibody dependent cellular cytotoxicity NSCLC
